Regulation of sarcoplasmic reticulum Ca2+ release by serine-threonine phosphatases in the heart

Journal of Molecular and Cellular Cardiology

Volumn 101, Issue , 2016, Pages 156-164

  Terentyev, Dmitry ^a   Hamilton, Shanna ^b  

^a BROWN UNIVERSITY   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cardiac arrhythmia; Heart failure; Ryanodine receptor; Sarcoplasmic reticulum calcium release; Serine threonine phosphatase

Indexed keywords

CALCINEURIN; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; RYANODINE RECEPTOR 2; SERINE; SERINE 2031; SERINE 2808; SERINE 2814; SPINOPHILIN; UNCLASSIFIED DRUG; CALCIUM; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BINDING; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ARRHYTHMOGENESIS; ARTICLE; ATRIAL FIBRILLATION; CALCIUM TRANSPORT; CARDIAC MUSCLE CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CARDIAC MUSCLE; CHEMISTRY; GENE INACTIVATION; GENETICS; HEART DISEASES; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CALCIUM; GENE KNOCKOUT TECHNIQUES; HEART DISEASES; HUMANS; MYOCARDIUM; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTEIN BINDING; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION;

EID: 84995920387     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.08.020     Document Type: Article

References (142)

1. [1] Bers, D.M., Cardiac excitation–contraction coupling. Nature 415 (2002), 198–205, 10.1038/415198a.
2. [2] Niggli, E., Ullrich, N.D., Gutierrez, D., Kyrychenko, S., Poláková, E., Shirokova, N., Posttranslational modifications of cardiac ryanodine receptors: Ca(2 +) signaling and EC-coupling. Biochim. Biophys. Acta 1833 (2013), 866–875, 10.1016/j.bbamcr.2012.08.016.
3. [3] Belevych, A.E., Terentyev, D., Terentyeva, R., Nishijima, Y., Sridhar, A., Hamlin, R.L., et al. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. Cardiovasc. Res. 90 (2011), 493–502, 10.1093/cvr/cvr025.
4. 2+-release but is precisely regulated by networks of associated proteins: a focus on proteins relevant to phosphorylation. Biochem. Soc. Trans. 43 (2015), 426–433, 10.1042/BST20140297.
5. 2+ current trigger. J. Physiol. Lond. 556 (2004), 463–480, 10.1113/jphysiol.2003.055384.
6. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J. Biol. Chem. 265 (1990), 13472–13483.
7. [7] Xiao, B., Jiang, M.T., Zhao, M., Yang, D., Sutherland, C., Lai, F.A., et al. Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. Circ. Res. 96 (2005), 847–855, 10.1161/01.RES.0000163276.26083.e8.
8. [8] Witcher, D.R., Kovacs, R.J., Schulman, H., Cefali, D.C., Jones, L.R., Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J. Biol. Chem. 266 (1991), 11144–11152.
9. 2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ. Res. 94 (2004), e61–e70, 10.1161/01.RES.0000125626.33738.E2.
10. [10] Jones, P.P., Meng, X., Xiao, B., Cai, S., Bolstad, J., Wagenknecht, T., et al. Localization of PKA phosphorylation site, Ser(2030), in the three-dimensional structure of cardiac ryanodine receptor. Biochem. J. 410 (2008), 261–270, 10.1042/BJ20071257.
11. [11] Yuchi, Z., Lau, K., Van Petegem, F., Disease mutations in the ryanodine receptor central region: crystal structures of a phosphorylation hot spot domain. Structure 20 (2012), 1201–1211, 10.1016/j.str.2012.04.015.
12. [12] Huttlin, E.L., Jedrychowski, M.P., Elias, J.E., Goswami, T., Rad, R., Beausoleil, S.A., et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143 (2010), 1174–1189, 10.1016/j.cell.2010.12.001.
13. [13] Brill, L.M., Xiong, W., Lee, K.-B., Ficarro, S.B., Crain, A., Xu, Y., et al. Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5 (2009), 204–213, 10.1016/j.stem.2009.06.002.
14. [14] Bers, D.M., Macromolecular complexes regulating cardiac ryanodine receptor function. J. Mol. Cell. Cardiol. 37 (2004), 417–429, 10.1016/j.yjmcc.2004.05.026.
15. [15] Zalk, R., Lehnart, S.E., Marks, A.R., Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76 (2007), 367–385, 10.1146/annurev.biochem.76.053105.094237.
16. [16] Li, J., Negro, A., Lopez, J., Bauman, A.L., Henson, E., Dodge-Kafka, K., et al. The mAKAPβ scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J. Mol. Cell. Cardiol. 48 (2010), 387–394, 10.1016/j.yjmcc.2009.10.023.
17. [17] Pare, G.C., The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J. Cell Sci. 118 (2005), 5637–5646, 10.1242/jcs.02675.
18. [18] Cohen, P.T., Cohen, P., Discovery of a protein phosphatase activity encoded in the genome of bacteriophage lambda. Probable identity with open reading frame 221. Biochem. J. 260 (1989), 931–934.
19. [19] MacDougall, L.K., Jones, L.R., Cohen, P., Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem. 196 (1991), 725–734.
20. [20] Heijman, J., Dewenter, M., El-Armouche, A., Dobrev, D., Function and regulation of serine/threonine phosphatases in the healthy and diseased heart. J. Mol. Cell. Cardiol. 64 (2013), 90–98, 10.1016/j.yjmcc.2013.09.006.
21. [21] Heroes, E., Lesage, B., Görnemann, J., Beullens, M., Van Meervelt, L., Bollen, M., The PP1 binding code: a molecular-lego strategy that governs specificity. Febs J. 280 (2013), 584–595, 10.1111/j.1742-4658.2012.08547.x.
22. [22] Herzig, S., Neumann, J., Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Physiol. Rev. 80 (2000), 173–210.
23. [23] Ceulemans, H., Bollen, M., Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol. Rev. 84 (2004), 1–39, 10.1152/physrev.00013.2003.
24. [24] Aoyama, H., Ikeda, Y., Miyazaki, Y., Yoshimura, K., Nishino, S., Yamamoto, T., et al. Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca(2 +) cycling. Cardiovasc. Res. 89 (2011), 79–88, 10.1093/cvr/cvq252.
25. [25] Liu, R., Correll, R.N., Davis, J., Vagnozzi, R.J., York, A.J., Sargent, M.A., et al. Cardiac-specific deletion of protein phosphatase 1β promotes increased myofilament protein phosphorylation and contractile alterations. J. Mol. Cell. Cardiol. 87 (2015), 204–213, 10.1016/j.yjmcc.2015.08.018.
26. [26] Cohen, P.T.W., Protein phosphatase 1—targeted in many directions. J. Cell Sci. 115 (2002), 241–256.
27. [27] Korrodi-Gregório, L., Esteves, S.L.C., Fardilha, M., Protein phosphatase 1 catalytic isoforms: specificity toward interacting proteins. Transl. Res. 164 (2014), 366–391, 10.1016/j.trsl.2014.07.001.
28. [28] Shi, Y., Serine/threonine phosphatases: mechanism through structure. Cell 139 (2009), 468–484, 10.1016/j.cell.2009.10.006.
29. [29] Lim, H.W., Molkentin, J.D., Calcineurin and human heart failure. Nat. Med. 5 (1999), 246–247, 10.1038/6430.
30. [30] Wolska, B.M., Calcineurin and cardiac function: is more or less better for the heart?. Am. J. Physiol. Heart Circ. Physiol. 297 (2009), H1576–H1577, 10.1152/ajpheart.00833.2009.
31. [31] Heineke, J., Ritter, O., Cardiomyocyte calcineurin signaling in subcellular domains: from the sarcolemma to the nucleus and beyond. J. Mol. Cell. Cardiol. 52 (2012), 62–73, 10.1016/j.yjmcc.2011.10.018.
32. [32] Wang, Y., Tandan, S., Hill, J.A., Calcineurin-dependent ion channel regulation in heart. Trends Cardiovasc. Med. 24 (2014), 14–22, 10.1016/j.tcm.2013.05.004.
33. [33] Marx, S.O., Reiken, S., Hisamatsu, Y., Gaburjakova, M., Gaburjakova, J., Yang, Y.M., et al. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers. J. Cell Biol. 153 (2001), 699–708.
34. [34] Marks, A.R., Marx, S.O., Reiken, S., Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers. Trends Cardiovasc. Med. 12 (2002), 166–170.
35. [35] Dodge-Kafka, K.L., Bauman, A., Mayer, N., Henson, E., Heredia, L., Ahn, J., et al. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J. Biol. Chem. 285 (2010), 11078–11086, 10.1074/jbc.M109.034868.
36. [36] Belevych, A.E., Sansom, S.E., Terentyeva, R., Ho, H.-T., Nishijima, Y., Martin, M.M., et al. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One, 6, 2011, e28324, 10.1371/journal.pone.0028324.
37. [37] El-Armouche, A., Rau, T., Zolk, O., Ditz, D., Pamminger, T., Zimmermann, W.H., et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J. 17 (2003), 437–439, 10.1096/fj.02-0057fje.
38. [38] Heijman, J., Spätjens, R.L.H.M.G., Seyen, S.R.M., Lentink, V., Kuijpers, H.J.H., Boulet, I.R., et al. Dominant-negative control of cAMP-dependent IKs upregulation in human long-QT syndrome type 1. Circ. Res. 110 (2012), 211–219, 10.1161/CIRCRESAHA.111.249482.
39. [39] DeGrande, S.T., Little, S.C., Nixon, D.J., Wright, P., Snyder, J., Dun, W., et al. Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart. J. Biol. Chem. 288 (2013), 1032–1046, 10.1074/jbc.M112.426957.
40. [40] Chen, J., Martin, B., Brautigan, D., Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257 (1992), 1261–1264, 10.1126/science.1325671.
41. [41] Lei, M., Wang, X., Ke, Y., Solaro, R.J., Regulation of Ca(2 +) transient by PP2A in normal and failing heart. Front. Physiol., 6, 2015, 13, 10.3389/fphys.2015.00013.
42. [42] Li, M., Guo, H., Damuni, Z., Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34 (1995), 1988–1996.
43. [43] Elton, T.S., Martin, M.M., Sansom, S.E., Belevych, A.E., Györke, S., Terentyev, D., miRNAs got rhythm. Life Sci. 88 (2011), 373–383, 10.1016/j.lfs.2010.11.022.
44. [44] Terentyev, D., Belevych, A.E., Terentyeva, R., Martin, M.M., Malana, G.E., Kuhn, D.E., et al. miR-1 overexpression enhances Ca(2 +) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ. Res. 104 (2009), 514–521, 10.1161/CIRCRESAHA.108.181651.
45. [45] Wang, J.-X., Jiao, J.-Q., Li, Q., Long, B., Wang, K., Liu, J.-P., et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat. Med. 17 (2011), 71–78, 10.1038/nm.2282.
46. [46] duBell, W.H., Lederer, W.J., Rogers, T.B., Dynamic modulation of excitation-contraction coupling by protein phosphatases in rat ventricular myocytes. J. Physiol. Lond. 493:Pt 3 (1996), 793–800, 10.1111/(ISSN)1469-7793.
47. [47] Santana, L.F., Chase, E.G., Votaw, V.S., Nelson, M.T., Greven, R., Functional coupling of calcineurin and protein kinase A in mouse ventricular myocytes. J. Physiol. Lond. 544 (2002), 57–69, 10.1113/jphysiol.2002.020552.
48. 2+ release. Circ. J. 73 (2009), 1133–1140, 10.1253/circj.CJ-08-0871.
49. 2+-release channels in rat heart. Biochem. J. 352 (2000), 61–70, 10.1042/bj3520061.
50. [50] Neumann, J., Boknik, P., Herzig, S., Schmitz, W., Scholz, H., Wiechen, K., et al. Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor. J. Pharmacol. Exp. Ther. 271 (1994), 535–541.
51. [51] Takasago, T., Imagawa, T., Shigekawa, M., Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J. Biochem. 106 (1989), 872–877.
52. [52] Takasago, T., Imagawa, T., Furukawa, K., Ogurusu, T., Shigekawa, M., Regulation of the cardiac ryanodine receptor by protein kinase-dependent phosphorylation. J. Biochem. 109 (1991), 163–170.
53. [53] Chu, A., Sumbilla, C., Inesi, G., Jay, S.D., Campbell, K.P., Specific association of calmodulin-dependent protein kinase and related substrates with the junctional sarcoplasmic reticulum of skeletal muscle. Biochemistry 29 (1990), 5899–5905.
54. [54] Wang, J., Best, P.M., Inactivation of the sarcoplasmic reticulum calcium channel by protein kinase. Nature 359 (1992), 739–741, 10.1038/359739a0.
55. [55] Lokuta, A.J., Rogers, T.B., Lederer, W.J., Valdivia, H.H., Modulation of cardiac ryanodine receptors of swine and rabbit by a phosphorylation-dephosphorylation mechanism. J. Physiol. Lond. 487:Pt 3 (1995), 609–622.
56. [56] Hain, J., Nath, S., Mayrleitner, M., Fleischer, S., Schindler, H., Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from skeletal muscle. Biophys. J. 67 (1994), 1823–1833, 10.1016/S0006-3495(94)80664-2.
57. [57] Hain, J., Onoue, H., Mayrleitner, M., Fleischer, S., Schindler, H., Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J. Biol. Chem. 270 (1995), 2074–2081.
58. [58] Marx, S.O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor). Cell 101 (2000), 365–376, 10.1016/S0092-8674(00)80847-8.
59. 2+ regulation. J. Membr. Biol. 240 (2011), 21–33, 10.1007/s00232-011-9339-9.
60. 2 + regulation. PLoS ONE, 8, 2013, e58334, 10.1371/journal.pone.0058334.
61. [61] Carter, S., Colyer, J., Sitsapesan, R., Maximum phosphorylation of the cardiac ryanodine receptor at serine-2809 by protein kinase a produces unique modifications to channel gating and conductance not observed at lower levels of phosphorylation. Circ. Res. 98 (2006), 1506–1513, 10.1161/01.RES.0000227506.43292.df.
62. [62] Györke, S., Terentyev, D., Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc. Res. 77 (2008), 245–255, 10.1093/cvr/cvm038.
63. 2+ release. J. Biol. Chem. 282 (2007), 30256–30264, 10.1074/jbc.M703510200.
64. [64] Huke, S., Bers, D.M., Ryanodine receptor phosphorylation at serine 2030, 2808 and 2814 in rat cardiomyocytes. Biochem. Biophys. Res. Commun. 376 (2008), 80–85, 10.1016/j.bbrc.2008.08.084.
65. [65] Chiang, D.Y., Li, N., Wang, Q., Alsina, K.M., Quick, A.P., Reynolds, J.O., et al. Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation. Cardiovasc. Res. 103 (2014), 178–187, 10.1093/cvr/cvu123.
66. [66] Terentyev, D., Viatchenko-Karpinski, S., Gyorke, I., Terentyeva, R., Györke, S., Protein phosphatases decrease sarcoplasmic reticulum calcium content by stimulating calcium release in cardiac myocytes. J. Physiol. Lond. 552 (2003), 109–118, 10.1113/jphysiol.2003.046367.
67. 2+ release. J. Physiol. Lond. 592 (2014), 1957–1973, 10.1113/jphysiol.2013.264689.
68. [68] Stange, M., Xu, L., Balshaw, D., Yamaguchi, N., Meissner, G., Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J. Biol. Chem. 278 (2003), 51693–51702, 10.1074/jbc.M310406200.
69. [69] Wehrens, X.H.T., Lehnart, S.E., Huang, F., Vest, J.A., Reiken, S.R., Mohler, P.J., et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113 (2003), 829–840, 10.1016/S0092-8674(03)00434-3.
70. [70] Huke, S., Bers, D.M., Temporal dissociation of frequency-dependent acceleration of relaxation and protein phosphorylation by CaMKII. J. Mol. Cell. Cardiol. 42 (2007), 590–599, 10.1016/j.yjmcc.2006.12.007.
71. 2+ handling in ageing rabbit hearts. J. Physiol. Lond. 591 (2013), 5895–5911, 10.1113/jphysiol.2013.260521.
72. [72] Wehrens, X.H.T., Lehnart, S.E., Reiken, S., Vest, J.A., Wronska, A., Marks, A.R., Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc. Natl. Acad. Sci. 103 (2006), 511–518, 10.1073/pnas.0510113103.
73. [73] Terentyev, D., Rees, C.M., Li, W., Cooper, L.L., Jindal, H.K., Peng, X., et al. Hyperphosphorylation of RyRs underlies triggered activity in transgenic rabbit model of LQT2 syndrome. Circ. Res. 115 (2014), 919–928, 10.1161/CIRCRESAHA.115.305146.
74. [74] van Oort, R.J., McCauley, M.D., Dixit, S.S., Pereira, L., Yang, Y., Respress, J.L., et al. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 122 (2010), 2669–2679, 10.1161/CIRCULATIONAHA.110.982298.
75. [75] Respress, J.L., van Oort, R.J., Li, N., Rolim, N., Dixit, S.S., deAlmeida, A., et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ. Res. 110 (2012), 1474–1483, 10.1161/CIRCRESAHA.112.268094.
76. [76] Ather, S., Wang, W., Wang, Q., Li, N., Anderson, M.E., Wehrens, X.H.T., Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy. Heart Rhythm. 10 (2013), 592–599, 10.1016/j.hrthm.2012.12.016.
77. [77] Li, N., Wang, T., Wang, W., Cutler, M.J., Wang, Q., Voigt, N., et al. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. Circ. Res. 110 (2012), 465–470, 10.1161/CIRCRESAHA.111.253229.
78. [78] Benkusky, N.A., Weber, C.S., Scherman, J.A., Farrell, E.F., Hacker, T.A., John, M.C., et al. Intact-adrenergic response and unmodified progression toward heart failure in mice with genetic ablation of a major protein kinase a phosphorylation site in the cardiac ryanodine receptor. Circ. Res. 101 (2007), 819–829, 10.1161/CIRCRESAHA.107.153007.
79. [79] MacDonnell, S.M., García-Rivas, G., Scherman, J.A., Kubo, H., Chen, X., Valdivia, H., et al. Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808. Circ. Res. 102 (2008), e65–e72, 10.1161/CIRCRESAHA.108.174722.
80. 2+ sensitivity. J. Mol. Cell. Cardiol. 53 (2012), 33–42, 10.1016/j.yjmcc.2012.03.015.
81. [81] Sarma, S., Li, N., van Oort, R.J., Reynolds, C., Skapura, D.G., Wehrens, X.H.T., Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 13165–13170, 10.1073/pnas.1004509107.
82. [82] Shan, J., Kushnir, A., Betzenhauser, M.J., Reiken, S., Li, J., Lehnart, S.E., et al. Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J. Clin. Invest. 120 (2010), 4388–4398, 10.1172/JCI32726.
83. [83] Neumann, J., Eschenhagen, T., Jones, L.R., Linck, B., Schmitz, W., Scholz, H., et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell. Cardiol. 29 (1997), 265–272, 10.1006/jmcc.1996.0271.
84. [84] Gupta, R.C., Mishra, S., Rastogi, S., Imai, M., Habib, O., Sabbah, H.N., Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 285 (2003), H2373–H2381, 10.1152/ajpheart.00442.2003.
85. [85] Huang, B., Wang, S., Qin, D., Boutjdir, M., El-Sherif, N., Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases. Circ. Res. 85 (1999), 848–855.
86. [86] Sande, J., Reduced level of serine16 phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc. Res. 53 (2002), 382–391, 10.1016/S0008-6363(01)00489-8.
87. [87] Münch, G., Bölck, B., Karczewski, P., Schwinger, R.H.G., Evidence for calcineurin-mediated regulation of SERCA 2a activity in human myocardium. J. Mol. Cell. Cardiol. 34 (2002), 321–334, 10.1006/jmcc.2001.1515.
88. [88] Williams, R.S., Calcineurin signaling in human cardiac hypertrophy. Circulation 105 (2002), 2242–2243.
89. [89] Ritter, O., Calcineurin in human heart hypertrophy. Circulation 105 (2002), 2265–2269, 10.1161/01.CIR.0000016044.19527.96.
90. [90] Yang, Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. Int. J. Mol. Med. 26 (2010), 159–164, 10.3892/ijmm_00000448.
91. [91] Briston, S.J., Caldwell, J.L., Horn, M.A., Clarke, J.D., Richards, M.A., Greensmith, D.J., et al. Impaired β-adrenergic responsiveness accentuates dysfunctional excitation-contraction coupling in an ovine model of tachypacing-induced heart failure. J. Physiol. Lond. 589 (2011), 1367–1382, 10.1113/jphysiol.2010.203984.
92. [92] Carr, A.N., Schmidt, A.G., Suzuki, Y., del Monte, F., Sato, Y., Lanner, C., et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22 (2002), 4124–4135, 10.1128/MCB.22.12.4124-4135.2002.
93. [93] El-Armouche, A., Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc. Res. 61 (2004), 87–93, 10.1016/j.cardiores.2003.11.005.
94. [94] Braz, J.C., Gregory, K., Pathak, A., Zhao, W., Sahin, B., Klevitsky, R., et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10 (2004), 248–254, 10.1038/nm1000.
95. 2+ leak in heart failure. Circ. Res. 97 (2005), 1314–1322, 10.1161/01.RES.0000194329.41863.89.
96. [96] Reiken, S., Gaburjakova, M., Gaburjakova, J., He, K.L., Prieto, A., Becker, E., et al. -Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104 (2001), 2843–2848, 10.1161/hc4701.099578.
97. [97] Doi, M., Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 105 (2002), 1374–1379, 10.1161/hc1102.105270.
98. [98] Reiken, S., Wehrens, X.H.T., Vest, J.A., Barbone, A., Klotz, S., Mancini, D., et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107 (2003), 2459–2466, 10.1161/01.CIR.0000068316.53218.49.
99. [99] Wijnker, P.J.M., Boknik, P., Gergs, U., Müller, F.U., Neumann, J., dos Remedios, C., et al. Protein phosphatase 2A affects myofilament contractility in non-failing but not in failing human myocardium. J. Muscle Res. Cell Motil. 32 (2011), 221–233, 10.1007/s10974-011-9261-x.
100. 2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ. Res. 91 (2002), 1015–1022.
101. [101] Antos, C.L., Frey, N., Marx, S.O., Reiken, S., Gaburjakova, M., Richardson, J.A., et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ. Res. 89 (2001), 997–1004, 10.1161/hh2301.100003.
102. [102] Reiken, S., Gaburjakova, M., Guatimosim, S., Gomez, A.M., D'Armiento, J., Burkhoff, D., et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J. Biol. Chem. 278 (2003), 444–453, 10.1074/jbc.M207028200.
103. [103] ORN, S., DICKSTEIN, K., How do heart failure patients die?. Eur. Heart J. 4 (2002), D59–D65, 10.1016/S0195-668X(02)80029-X.
104. [104] Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., Butler, J., The sympathetic nervous system in heart failure. J. Am. Coll. Cardiol. 54 (2009), 1747–1762, 10.1016/j.jacc.2009.05.015.
105. [105] DeSantiago, J., Ai, X., Islam, M., Acuna, G., Ziolo, M.T., Bers, D.M., et al. Arrhythmogenic effects of 2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ. Res. 102 (2008), 1389–1397, 10.1161/CIRCRESAHA.107.169011.
106. [106] Pogwizd, S., Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc. Med. 14 (2004), 61–66, 10.1016/j.tcm.2003.12.002.
107. [107] Janse, M., Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc. Res. 61 (2004), 208–217, 10.1016/j.cardiores.2003.11.018.
108. 2+-calmodulin-dependent protein kinase II. J. Mol. Cell. Cardiol. 49 (2010), 25–32, 10.1016/j.yjmcc.2010.03.013.
109. [109] Baartscheer, A., Schumacher, C., Belterman, C., Coronel, R., Fiolet, J., SR calcium handling and calcium after-transients in a rabbit model of heart failure. Cardiovasc. Res. 58 (2003), 99–108, 10.1016/S0008-6363(02)00854-4.
110. [110] Venetucci, L.A., Trafford, A.W., O'Neill, S.C., Eisner, D.A., The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc. Res. 77 (2008), 285–292, 10.1093/cvr/cvm009.
111. [111] Monsuez, J.J., Papon, B.J., Lachurié, M.L., Passeron, J., Sudden cardiac death in heart failure: the role of abnormal repolarization. Circulation 91 (1995), 1899–1900.
112. [112] ter Keurs, H.E.D.J., Boyden, P.A., Calcium and arrhythmogenesis. Physiol. Rev. 87 (2007), 457–506, 10.1152/physrev.00011.2006.
113. [113] Xie, L.H., Weiss, J.N., Arrhythmogenic consequences of intracellular calcium waves. Am. J. Physiol. Heart Circ. Physiol. 297 (2009), H997–H1002, 10.1152/ajpheart.00390.2009.
114. 2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ. Res. 107 (2010), 1150–1161, 10.1161/CIRCRESAHA.110.220418.
115. [115] Rodriguez, P., Mitton, B., Nicolaou, P., Chen, G., Kranias, E.G., Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 293 (2007), H762–H769, 10.1152/ajpheart.00104.2007.
116. [116] El-Armouche, A., Wittköpper, K., Degenhardt, F., Weinberger, F., Didié, M., Melnychenko, I., et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc. Res. 80 (2008), 396–406, 10.1093/cvr/cvn208.
117. [117] Heijman, J., Algalarrondo, V., Voigt, N., Melka, J., Wehrens, X.H.T., Dobrev, D., et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc. Res. 109 (2016), 467–479, 10.1093/cvr/cvv275.
118. [118] Hove-Madsen, L., Llach, A., Bayes-Genís, A., Roura, S., Rodriguez Font, E., Arís, A., et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation 110 (2004), 1358–1363, 10.1161/01.CIR.0000141296.59876.87.
119. [119] Vest, J.A., Wehrens, X.H.T., Reiken, S.R., Lehnart, S.E., Dobrev, D., Chandra, P., et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111 (2005), 2025–2032, 10.1161/01.CIR.0000162461.67140.4C.
120. 2+ handling in human chronic atrial fibrillation. Circulation 114 (2006), 670–680, 10.1161/CIRCULATIONAHA.106.636845.
121. [121] Greiser, M., Neuberger, H.-R., Harks, E., El-Armouche, A., Boknik, P., de Haan, S., et al. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J. Mol. Cell. Cardiol. 46 (2009), 385–394, 10.1016/j.yjmcc.2008.11.012.
122. 2 + levels in right atrial myocardium of patients with atrial fibrillation. Circ. Res. 106 (2010), 1134–1144, 10.1161/CIRCRESAHA.109.203836.
123. 2+ leak promotes atrial fibrillation in mice. J. Clin. Invest. 119 (2009), 1940–1951, 10.1172/JCI37059.
124. 2+ exchanger function underlie delayed after depolarizations in patients with chronic atrial fibrillation. Circulation 125 (2012), 2059–2070, 10.1161/CIRCULATIONAHA.111.067306.
125. [125] DeGrande, S., Nixon, D., Koval, O., Curran, J.W., Wright, P., Wang, Q., et al. CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome. Heart Rhythm. 9 (2012), 2034–2041, 10.1016/j.hrthm.2012.08.026.
126. [126] Bennett, V., Baines, A.J., Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol. Rev. 81 (2001), 1353–1392.
127. [127] Smith, S., Curran, J., Hund, T.J., Mohler, P.J., Defects in cytoskeletal signaling pathways, arrhythmia, and sudden cardiac death. Front. Physiol., 3, 2012, 10.3389/fphys.2012.00122.
128. [128] Bhasin, N., Cunha, S.R., Mudannayake, M., Gigena, M.S., Rogers, T.B., Mohler, P.J., Molecular basis for PP2A regulatory subunit B56 targeting in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 293 (2007), H109–H119, 10.1152/ajpheart.00059.2007.
129. [129] Cunha, S.R., Mohler, P.J., Obscurin targets ankyrin-B and protein phosphatase 2A to the cardiac M-line. J. Biol. Chem. 283 (2008), 31968–31980, 10.1074/jbc.M806050200.
130. [130] Mohler, P.J., Splawski, I., Napolitano, C., Bottelli, G., Sharpe, L., Timothy, K., et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc. Natl. Acad. Sci. 101 (2004), 9137–9142, 10.1073/pnas.0402546101.
131. [131] Mohler, P.J., Schott, J.-J., Gramolini, A.O., Dilly, K.W., Guatimosim, S., duBell, W.H., et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421 (2003), 634–639, 10.1038/nature01335.
132. [132] Brunner, M., Peng, X., Liu, G.X., Ren, X.-Q., Ziv, O., Choi, B.-R., et al. Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J. Clin. Invest. 118 (2008), 2246–2259, 10.1172/JCI33578.
133. [133] Heineke, J., Molkentin, J.D., Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7 (2006), 589–600, 10.1038/nrm1983.
134. [134] Panther, F., Williams, T., Ritter, O., Inhibition of the calcineurin-NFAT signalling cascade in the treatment of heart failure. Recent Pat. Cardiovasc. Drug Discov. 4 (2009), 180–186, 10.2174/157489009789152276.
135. [135] Lim, S., Smith, K.R., Lim, S.-T.S., Tian, R., Lu, J., Tan, M., Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation. Cell Biosci., 6, 2016, 33, 10.1186/s13578-016-0089-3.
136. [136] Rosini, J.M., Rajasimhan, S., Fellows, S.E., Nomura, J.T., Delayed cardiac dysrhythmias after fingolimod administration. Am. J. Emerg. Med. 33 (2015), 987.e1–987.e3, 10.1016/j.ajem.2014.12.037.
137. [137] Egom, E.E.A., Ke, Y., Musa, H., Mohamed, T.M.A., Wang, T., Cartwright, E., et al. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J. Mol. Cell. Cardiol. 48 (2010), 406–414, 10.1016/j.yjmcc.2009.10.009.
138. [138] Mourer, J.S., Ewe, S.H., Mallat, M.J.K., Ng, A.C.T., Rabelink, T.J., Bax, J.J., et al. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. Transp. J. 94 (2012), 721–728, 10.1097/TP.0b013e3182603297.
139. [139] Hiemstra, J.A., Gutierrez-Aguilar, M., Marshall, K.D., McCommis, K.S., Zgoda, P.J., Cruz-Rivera, N., et al. A new twist on an old idea part 2: cyclosporine preserves normal mitochondrial but not cardiomyocyte function in mini-swine with compensated heart failure. Phys. Rep., 2, 2014, e12050, 10.14814/phy2.12050.
140. [140] Little, S.C., Curran, J., Makara, M.A., Kline, C.F., Ho, H.-T., Xu, Z., et al. Protein phosphatase 2A regulatory subunit B56α limits phosphatase activity in the heart. Sci. Signal., 8, 2015, ra72-ra72, 10.1126/scisignal.aaa5876.
141. [141] Kirchhefer, U., Brekle, C., Eskandar, J., Isensee, G., Kučerová, D., Müller, F.U., et al. Cardiac function is regulated by B56α-mediated targeting of protein phosphatase 2A (PP2A) to contractile relevant substrates. J. Biol. Chem. 289 (2014), 33862–33873, 10.1074/jbc.M114.598938.
142. [142] Nicolaou, P., Hajjar, R.J., Kranias, E.G., Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J. Mol. Cell. Cardiol. 47 (2009), 365–371, 10.1016/j.yjmcc.2009.05.010.